Well done, Peach. In order to be up 100%, I am presuming that you either (1) Did not buy in until AFTER the sp cratered down, or (2) Traded in and out to lower your avg cost basis?
Either way, you did well and were one of the few unscathed ones.
Happy for you, Peach…
LOL, we are only 4 trading days into 2015, Peach, and you are asking for a crystal ball to see the end of 2015 already? LOL…
Too many unknown variables at this time. Depending on how significant the other business segments become, Main Ave may or may not have to carry the entire SCRC burden on its own. If it does, then the sp projections will be one thing. But if RapiMed actually launches and becomes even a moderate success that can be even half of what Main Ave is (even though BS Schneiderman went on record stating that RapiMed should equal Main Ave), then that changes the calculus upwards in a big way.
Same thing with the partnerships w/United Apothecary and Jungle Jim’s. With so many more states that these partnerships bring to the table, if they can bring in even a quarter of what Main Ave brings, that will be huge as well.
Same thing with PIMD, although at this time I personally think that PIMD will only be a very minor contributor, just like WRx.
The important thing is GROWTH and not FLATLINING revenues/earnings. Why? Because growth is the reason the Street awards a multiple. And a multiple is the most meaningful way to grow a sp. If SCRC continues to generate growth, then there are voices here that suggest a 10-15x multiple. BUT, if revenues/earnings become flat (still profitable, but just NOT growing MORE profitable), the question becomes whether the Street will still award SCRC’s sp with anything close to a 10-15x multiple.
So whether Main Ave finds a way to grow in a material way, and if other business segments bear meaningful fruit, will be significant factors in what SCRC’s sp will be at the end of 2015.